Login to Your Account

Financings Roundup

Mpex Successor Rempex Snags up to $67.5M in Series B

By Marie Powers
Staff Writer

Thursday, November 10, 2011

Rempex Pharmaceuticals Inc., formed in June to acquire the human, financial and clinical assets unrelated to Aeroquin from Mpex Pharmaceuticals Inc., has attracted a commitment of up to $67.5 million to advance the development of treatments for resistant Gram-negative infections.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription